Breast Cancer Research – Dr. Speyer
For the past five years, my collaborator and I have identified and established a role for the metabotropic glutamate receptor-1 (mGluR1) in breast cancer. Our specific focus includes i) determining the mechanism and novel pathways by which mGluR1 regulates the angiogenic process in endothelial cells ii) examining the molecular pathways by which mGluR1 mediates growth and metastatic properties of breast cancer cells iii) elucidating the mGluR1-dependent and independent role of the drug, Riluzole, in regulating breast tumor progression iv) examining the anti-inflammatory properties of mGluR1 and Riluzole within the tumor microenvironment.
My past research focus has been in the area of inflammation where I discovered the expression of novel chemokine receptors on neutrophils in sepsis. These findings have shed light on the concept of neutrophil subsets in various chronic inflammatory diseases such as sepsis, autoimmune diseases, and cancer. Currently, my laboratory’s focus is expanding into the area of tumor inflammation where we are examining the role and function of the various PMN subsets, their expression of various receptors (CC chemokine, mGluR1), and the role of the receptors themselves within the tumor microenvironment in the hopes of identifying targets for the therapeutic treatment of breast cancer